Lower prices from the third round of talks among Medicare and manufacturers will be announced in the fall but won’t go into ...

Mid-stage trial data showed Roche's experimental shot delivered weight loss on par with leading obesity treatments, ...

Here & Now’s Peter O’Dowd spoke with Sarah Zhang, a reporter for The Atlantic, about how people are searching the web and using the app Telegram to buy next-generation GLP-3 drugs not yet approved by ...

Investing.com -- Roche Holding AG (SIX:RO) on Tuesday announced positive Phase II results for its dual GLP-1/GIP receptor agonist CT-388 in people living with obesity. The drug achieved 22.5% ...